1. A preliminary assessment of longitudinal amyloid status in the ongoing open‐label extension phase in subjects with early Alzheimer's disease: Human/Human trials: Anti‐amyloid. (7th December 2020) Authors: Swanson, Chad J.; Zhang, Yong; Dhadda, Shobha; Wang, Jinping; Kaplow, June; Bradley, Heather; Rabe, Martin; Lai, Robert Y.K.; Gordon, Robert; Kramer, Lynn D. Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ADCOMS: a composite clinical outcome for prodromal Alzheimer's disease trials. Issue 9 (23rd March 2016) Authors: Wang, Jinping; Logovinsky, Veronika; Hendrix, Suzanne B; Stanworth, Stephanie H; Perdomo, Carlos; Xu, Lu; Dhadda, Shobha; Do, Ira; Rabe, Martin; Luthman, Johan; Cummings, Jeffrey; Satlin, Andrew Journal: Journal of neurology, neurosurgery and psychiatry Issue: Volume 87:Issue 9(2016) Page Start: 993 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. AHEAD 3‐45 study design: A global study to evaluate the efficacy and safety of treatment with BAN2401 for 216 weeks in preclinical Alzheimer's disease with intermediate amyloid (A3 trial) and elevated amyloid (A45 trial): Clinical trial design and implementation. (7th December 2020) Authors: Aisen, Paul S.; Zhou, Jin; Irizarry, Michael C.; Kramer, Lynn D; Swanson, Chad J.; Dhadda, Shobha; Rabe, Martin; Krause, Stephen; Li, David JianJun; Raman, Rema; Donohue, Michael C.; Sethuraman, Gopalan; Johnson, Keith A.; Sperling, Reisa A. Journal: Alzheimer's & dementia Issue: Volume 16(2020)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. AHEAD 3‐45 study: Preliminary screening and baseline characteristics from a placebo‐controlled, double‐blind study evaluating lecanemab in participants with preclinical Alzheimer's disease and elevated (A45 trial) and intermediate (A3 trial) amyloid. (31st December 2021) Authors: Zhou, Jin; Irizarry, Michael C; Kramer, Lynn D; Swanson, Chad J; Roberts, Claire; Dhadda, Shobha; Li, David JianJun; Rabe, Martin; Krause, Stephen; Raman, Rema; Donohue, Michael C; Sethuraman, Gopalan; Johnson, Keith A.; Sperling, Reisa A.; Aisen, Paul S Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. Issue 1 (20th March 2023) Authors: Honig, Lawrence S.; Barakos, Jerome; Dhadda, Shobha; Kanekiyo, Michio; Reyderman, Larisa; Irizarry, Michael; Kramer, Lynn D.; Swanson, Chad J.; Sabbagh, Marwan Journal: Alzheimer's & dementia Issue: Volume 9:Issue 1(2023) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Baseline characteristics for CLARITY AD: A phase 3 placebo‐controlled, double‐blind, parallel‐group, 18‐month study evaluating lecanemab (ban2401) in early Alzheimer's disease. (31st December 2021) Authors: Lynch, Shau Yu; Irizarry, Michael C; Dhadda, Shobha; Li, David JianJun; Kanekiyo, Michio; Bogoslovsky, Tanya; Gee, Michelle; Reyderman, Larisa; Kaplow, June; Rabe, Martin; Hodgkinson, Mark; Kramer, Lynn D; Hampel, Harald; Swanson, Chad J Journal: Alzheimer's & dementia Issue: Volume 17(2021)Supplement 9 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Baseline regional Tau distribution predicts fast cognitive decline in subjects with mild cognitive impairment. (20th December 2022) Authors: Charil, Arnaud; Devanarayan, Viswanath; Murali, Leema; Qi, Xin; Krause, Stephen; Sachdev, Pallavi; Reyderman, Larisa; Koyama, Akihiko; Dhadda, Shobha; Irizarry, Michael C Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 5 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Derivation and evaluation of signatures using plasma β‐amyloid and pTau‐181 for brain amyloid‐β detection. (20th December 2022) Authors: Devanarayan, Viswanath; Dhadda, Shobha; Koyama, Akihiko; Swanson, Chad J; Hampel, Harald; Irizarry, Michael C; Kramer, Lynn D Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 5 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease. Issue 1 (4th February 2016) Authors: Satlin, Andrew; Wang, Jinping; Logovinsky, Veronika; Berry, Scott; Swanson, Chad; Dhadda, Shobha; Berry, Donald A. Journal: Alzheimer's & dementia Issue: Volume 2:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Development and validation of AI‐based tools for brain amyloid‐β detection using MRI. (20th December 2022) Authors: Devanarayan, Viswanath; Charil, Arnaud; Nelson, Todd; Qi, Xin; Murali, Leema; Reyderman, Larisa; Irizarry, Michael C; Koyama, Akihiko; Dhadda, Shobha Journal: Alzheimer's & dementia Issue: Volume 18(2022)Supplement 5 Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗